IL151992A0 - Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists - Google Patents

Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Info

Publication number
IL151992A0
IL151992A0 IL15199201A IL15199201A IL151992A0 IL 151992 A0 IL151992 A0 IL 151992A0 IL 15199201 A IL15199201 A IL 15199201A IL 15199201 A IL15199201 A IL 15199201A IL 151992 A0 IL151992 A0 IL 151992A0
Authority
IL
Israel
Prior art keywords
treatment
growth factor
receptor antagonists
vascular endothelial
factor receptor
Prior art date
Application number
IL15199201A
Other languages
English (en)
Original Assignee
Imclone Systems Inc
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Cornell Res Foundation Inc filed Critical Imclone Systems Inc
Publication of IL151992A0 publication Critical patent/IL151992A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL15199201A 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists IL151992A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54077000A 2000-03-31 2000-03-31
PCT/US2001/010504 WO2001074296A2 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Publications (1)

Publication Number Publication Date
IL151992A0 true IL151992A0 (en) 2003-04-10

Family

ID=24156859

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15199201A IL151992A0 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Country Status (10)

Country Link
EP (1) EP1436000A2 (ja)
JP (1) JP2004501070A (ja)
KR (1) KR20020087453A (ja)
AU (1) AU2001249736A1 (ja)
CA (1) CA2404040A1 (ja)
CZ (1) CZ20023518A3 (ja)
IL (1) IL151992A0 (ja)
RU (1) RU2002129574A (ja)
SK (1) SK15302002A3 (ja)
WO (1) WO2001074296A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
SI1343782T1 (sl) 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
JP2005515967A (ja) * 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
DE60333554D1 (de) 2002-03-04 2010-09-09 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
MXPA06002296A (es) 2003-08-29 2006-05-22 Pfizer Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
MXPA06007242A (es) 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
BR112014010774A2 (pt) 2011-11-02 2017-06-13 Apexigen Inc anticorpos anti-kdr e métodos de uso

Also Published As

Publication number Publication date
RU2002129574A (ru) 2004-04-20
CZ20023518A3 (cs) 2004-04-14
CA2404040A1 (en) 2001-10-11
WO2001074296A3 (en) 2004-05-06
EP1436000A2 (en) 2004-07-14
WO2001074296A2 (en) 2001-10-11
AU2001249736A1 (en) 2001-10-15
JP2004501070A (ja) 2004-01-15
KR20020087453A (ko) 2002-11-22
SK15302002A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
IL157693A0 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
HUP0201480A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
SG117417A1 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
IL198800A0 (en) Growth differentiation factor receptors, agonists and antagonists thereof and methods of using same
EP1385862A4 (en) VASCULAR ENDOTHEL GROWTH FACTOR 2
AU8298201A (en) Sutures and coatings made from therapeutic absorbable glass
EP1313512A4 (en) LIKE ENDOTH GROWTH FACTOR 2 (VEGF-2)
EP1487490A4 (en) COMBINATION OF TUMOR GROWTH INHIBITION METHODS USING A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST
AU9500201A (en) Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU5023300A (en) Vascular endothelial growth factor variants
HUP0203246A3 (en) Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
FR2794019B1 (fr) Implant d'osteosynthese
HUP0200827A3 (en) Vascular endothelial cell growth factor variants and uses thereof
IL151992A0 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
AU2001277524A1 (en) Novel use of inhibitors of the epidermal growth factor receptor
AU2003216389A8 (en) Induction of hair growth with vascular endothelial growth factor
IL145051A0 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
HUP0101520A3 (en) Biologically degradable cement exhibiting improved properties
IS5999A (is) Beinvaxtarörvandi þáttur
EP1323736A4 (en) CHIMERIC GROWTH FACTOR OF HUMAN TYPE VASCULAR ENDOTHELIAL CELLS
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
ZA200109347B (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists.
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists
TW412998U (en) Structure of cup with heat-insulating effects
GB0002527D0 (en) Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction